Literature DB >> 15069309

Complications of androgen deprivation therapy for prostate cancer.

Jeffrey M Holzbeierlein1, Matthew D McLaughlin, J Brantley Thrasher.   

Abstract

PURPOSE OF REVIEW: Androgen deprivation as a form of treatment for prostate cancer has been used for decades. Within the last decade, however, there has been a significant increase in its use. Therefore, it is incumbent upon the physician to be familiar with the side effects associated with this treatment. RECENT
FINDINGS: Some of the side effects such as osteoporosis, changes in lipid profiles, and anemia may have significant morbidity associated with them, while other side effects such as impotence, decreased libido, fatigue, and hot flashes primarily affect the patient's quality of life. Prevention strategies and treatments exist for many of these side effects.
SUMMARY: This review will update physicians treating patients with androgen deprivation therapy on the side effects associated with this treatment. Once physicians are aware of the potential side effects, they can educate patients on what to expect when starting androgen deprivation therapy. More importantly, physicians can now prevent some of these complications prior to their occurrence, and when these complications occur they have knowledge of the latest treatments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15069309     DOI: 10.1097/00042307-200405000-00007

Source DB:  PubMed          Journal:  Curr Opin Urol        ISSN: 0963-0643            Impact factor:   2.309


  23 in total

1.  Tissue-selective regulation of androgen-responsive genes.

Authors:  Maya Otto-Duessel; Miaoling He; Jeremy O Jones
Journal:  Endocr Res       Date:  2012-05-16       Impact factor: 1.720

2.  Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  Arch Intern Med       Date:  2006-02-27

3.  Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  J Natl Cancer Inst       Date:  2006-06-21       Impact factor: 13.506

Review 4.  Hypogonadism and its treatment among prostate cancer survivors.

Authors:  Edward J Choi; Perry Xu; Farouk M El-Khatib; Linda M Huynh; Faysal A Yafi
Journal:  Int J Impot Res       Date:  2020-12-12       Impact factor: 2.896

5.  A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.

Authors:  Robert S DiPaola; Yu-Hui Chen; Glenn J Bubley; Mark N Stein; Noah M Hahn; Michael A Carducci; Edmund C Lattime; James L Gulley; Philip M Arlen; Lisa H Butterfield; George Wilding
Journal:  Eur Urol       Date:  2014-12-18       Impact factor: 20.096

Review 6.  Quality of life issues in men undergoing androgen deprivation therapy: a review.

Authors:  Rowan G Casey; Niall M Corcoran; S Larry Goldenberg
Journal:  Asian J Androl       Date:  2012-01-09       Impact factor: 3.285

7.  The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells.

Authors:  Mugdha Patki; Venkatesh Chari; Suneethi Sivakumaran; Mesfin Gonit; Robert Trumbly; Manohar Ratnam
Journal:  J Biol Chem       Date:  2013-02-20       Impact factor: 5.157

8.  Estrogenic side effects of androgen deprivation therapy.

Authors:  Theresa A Guise; Michael G Oefelein; James A Eastham; Michael S Cookson; Celestia S Higano; Matthew Raymond Smith
Journal:  Rev Urol       Date:  2007

9.  The ternary complex factor protein ELK1 is an independent prognosticator of disease recurrence in prostate cancer.

Authors:  Luke Pardy; Rayna Rosati; Claire Soave; Yanfang Huang; Seongho Kim; Manohar Ratnam
Journal:  Prostate       Date:  2019-12-03       Impact factor: 4.104

10.  Characteristics of urologists predict the use of androgen deprivation therapy for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-fang Kuo; Jean L Freeman; Eduardo Orihuela; James S Goodwin
Journal:  J Clin Oncol       Date:  2007-12-01       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.